



#### Cleveland Clinic Laboratories


#### Technical Update • September-October 2014

Cleveland Clinic Laboratories is dedicated to keeping you updated and informed about recent testing changes. That's why we are happy to provide this technical update on a monthly basis.

Recently changed tests are **bolded**, and could include revisions to methodology, reference range, days performed or CPT code. For your convenience, tests are listed alphabetically and the order and billing codes are provided.

If you wish to compare the new information with previous test demographics, refer to the Test Directory, which can be accessed at clevelandcliniclabs.com.

Deleted tests and new tests are listed separately. Please update your database as necessary. For additional detail, contact Client Services at 216.444.5755 or 800.628.6816 or via email at clientservices@ccf.org.




# Rest NADARE #

# Summary of Changes by Test Name

# 

Diagnostic CTTR Intron 8  Diagnostic CTTR Intron 9  Diagnostic CTTR In					•			
10 Ear Culture and Stain 11 Eye Culture 11 Eye Culture and Stain 12 Febrospect II 13 Febrospect II 14 Fibrospect II 15 Fibrospect II 16 Fibrospect II 17 Fibrospect II 18 Fibrospect II 19 Fibrospect II 19 Fibrospect II 10 Fibrospect II 10 Fibrospect II 11 Fibrospect II 11 Fibrospect II 12 Fibrospect II 13 Fibrospect II 14 Fibrospect II 15 Fibrospect II 16 Fibrospect II 17 Fibrospect II 18 Fibrospect II 18 Fibrospect II 19 Fibrospect II 19 Fibrospect II 10 Fibrospect II 10 Fibrospect II 10 Fibrospect II 11 Fibrospect II 11 Fibrospect II 11 Fibrospect II 12 Fibrospect II 13 Fibrospect II 14 Fibrospect II 15 Fibrospect II 16 Fibrospect II 16 Fibrospect II 17 Fibrospect II 18 Fibrospect II 19 Fibrospect II 19 Fibrospect II 19 Fibrospect II 10 Fibrospect II 11 Fibrospect II 11 Fibrospect II 11 Fibrospect II 11 Fibrospect II 12 Fibrospect II 13 Fibrospect II 14 Fibrospect II 15 Fibrospect II 16 Fibrospect II 16 Fibrospect II 16 Fibrospect II 17 Fibrospect II 18 Fibrospect II 18 Fibrospect II 18 Fibrospect II 19 Fibrospect II 19 Fibrospect II 19 Fibrospect II 19 Fibrospect II 10 Fibrospect II 10 Fibrospect II 10 Fibrospect II 10 Fibrospect II 11 Fibrospect II 12 Fibros	16	Diagnostic CFTR Intron 8						
11 Eye Culture 11 Eye Culture and Stain 12 Fibrospect II 12 Fibrospect II 13 Fibrospect II 14 Fibrospect II 15 Fibr for Angiosarcoma MYC Amplification 15 Fibrov Cytometry for Myeloma 16 Hamaglobinopathy Evaluation 17 Histoplasma Antigen by EIA, Body Fluid 18 Histoplasma Capsulaturi Antigen 18 Hiv-18 Fibrov Confirmation 19 Histoplasma Capsulaturi Antigen 19 Hiv-2 Antibody Confirmation, Serum 10 Hiv-2 Roft Abs., Confirmation 11 Hiv-2 Roft Abs., Confirmation 12 Hiv-2 Roft Abs., Confirmation 13 Hiv-2 Antibody Confirmation 14 Hiv-2 Roft Abs., Confirmation 15 Hiv-2 Roft Abs., Confirmation 16 Hiv-2 Roft Abs., Confirmation 17 Hiv-2 Roft Abs., Confirmation 18 Hiv-2 Antibodies (IGG4) 19 Roft Abs., Confirmation 19 Roft Abs., Confirmation 10 Roft Abs., Confirmation 10 Roft Abs., Confirmation 10 Roft Abs., Confirmation 10 Roft Abs., Confirmation 11 Roft Abs., Confirmation 11 Roft Abs., Confirmation 12 Roft Abs., Confirmation 13 Roft Roft Abs., Confirmation 14 Roft Abs., Confirmation 15 Roft Roft Abs., Confirmation 16 Roft Abs., Confirmation 16 Roft Abs., Confirmation 17 Roft Roft Abs., Confirmation 18 Roft Roft Roft Roft Roft Roft Roft Roft	10	Ear Culture						
11 Eye Culture and Stain 5 Fentanyl and Metabolite, Urine 12 Fibrospect II 12 Fish for Angiosarcoma MYC Amplification 5 Fiow Cytemetry for Myeloma 5 Fiow Cytemetry for Myeloma 12 Histoplasma Antigen by EIA, Body Fluid 12 Histoplasma Antigen by EIA, Body Fluid 13 HiV-1 RNA, Qual TMA 13 HiV-2 Antibody Confirmation, Serum 14 Hiv-1 RNA, Qual TMA 15 HiV-2 RSA, Confirmation, Serum 16 Hiv-2 (gA Sox, Confirmation) 17 Hiv-1 RNA, Qual TMA 18 Hiv-2 Antibody Confirmation Serum 19 Hiv-2 RSA, Gods, Confirmation 19 Hiv-2 (gA Sox, Confirmation) 10 Hiv-2 (gA Sox, Confirmation) 10 Hiv-2 (gA Sox, Confirmation) 11 Hiv-2 (gA Sox, Confirmation) 12 Hiv-2 RNA, Qual TMA 13 Hiv-2 RNA, Qual TMA 14 Hiv-2 RNA, Qual TMA 15 Hiv-2 RNA, Qual TMA 16 Hiv-2 (gA Sox, Confirmation) 17 Hiv-2 RNA, Qual TMA 18 Hiv-2 RNA, Qual TMA 19 Hiv-2 RNA, Qual TMA 19 His-3 RNA, Qual TMA 19 His-3 RNA, Qual TMA 19 His-3 RNA, Qual TMA 10 Hiv-2 RNA, Qual TMA 10 Hiv-2 RNA, Qual TMA 10 Hiv-2 RNA, Qual TMA 11 Hiv-2 RNA, Qual TMA 11 Hiv-2 RNA, Qual TMA 12 His-3 RNA, Qual TMA 13 Hiv-2 RNA, Qual TMA 14 His-3 RNA, Qual TMA 15 India RNA, Qual TMA 16 India RNA, Qual TMA 17 His-3 RNA, Qual TMA 18 Hiv-2 RNA, Qual TMA 18 Hiv-2 RNA, Qual TMA 19 His-3 RNA, Qual TMA 19 His-3 RNA, Qual TMA 10 His-3 RNA, Qual TMA 10 His-3 RNA, Qual TMA 10 His-3 RNA, Qual TMA 11 His-3 RNA, Qual TMA 11 His-3 RNA, Qual TMA 12 His-3 RNA, Qual TMA 13 Hiv-2 RNA, Qual TMA 14 His-3 RNA, Qual TMA 15 RNA, Qual TMA 16 Potein Edectophoresis, Fluid 16 Protein Edectophoresis, Fluid 17 Protein Edectophoresis, Fluid 18 Protein Edectophoresis, Fluid 19 Protein Edectophoresis, Fluid 10 Protein Edectophoresis, Fluid 10 Protein Edectophoresis, Fluid 10 Protein Edectophoresis, Fluid 10 Protein Edectophoresis, Fluid 11 RNA, Status	10	Ear Culture and Stain						
5 Fentanyl and Metabolite, Urine 12 Fibrospect II 12 Fibrospect II 15 Fibrospect II 16 Fibrospect II 17 Fibrospect II 18 Fibrospect II 18 Fibrospect II 19 Fibrospect II 19 Fibrospect II 19 Fibrospect II 10 Fibrospect II 10 Fibrospect II 11 Fibrospect II 11 Fibrospect II 12 Histoplasma Antigen by EIA, Body Fluid 12 Histoplasma Antigen by EIA, Serum 16 Histoplasma Capsulatum Antigen 18 Hiv-I RNA, Qual TMA 18 Hiv-Z Antibody Confirmation, Serum 19 Hiv-Z III 10 Hiv-Z III 11 Fibrospect II 11 Fibrospect II 12 Fibrospect II 13 Hiv-I RNA, Qual TMA 19 Hiv-Z Antibody Confirmation 10 HIV-Z III 11 Fibrospect II 11 Fibrospect II 12 Fibrospect II 13 Hiv-I RNA, Qual TMA 19 Hiv-Z III 10 Fibrospect II 10 Hiv-Z III 11 Fibrospect II 11 Fibrospect II 12 Fibrospect II 13 Fibrospect II 14 Fibrospect II 15 Fibrospect II 16 Fibrospect II 17 Fibrospect II 18 Fibrospect II 18 Fibrospect II 19 Fibrospect II 19 Fibrospect II 19 Fibrospect II 19 Fibrospect II 10 Fibrospect II 10 Fibrospect II 10 Fibrospect II 11 Fibrospect II 11 Fibrospect II 12 Fibrospect II 13 Fibrospect II 14 Fibrospect II 15 Fibrospect II 16 Fibrospect II 17 Fibrospect II 18 Fibrospect II 19 Fibrospect II 19 Fibrospect II 19 Fibrospect II 10 Fibrospect II 10 Fibrospect II 11 Fibrospect II 11 Fibrospect II 12 Fibrospect II 13 Fibrospect II 14 Fibrospect II 15 Fibrospect II 16 Fibrospect II 17 Fibrospect II 18 Fibrospect II 18 Fibrospect II 19 Fibrospect II 19 Fibrospect II 19 Fibrospect II 19 Fibrospect II 10 Fibrospect II 10 Fibrospect II 11 Fibrospect II 12 Fibrospect II 13 Fibrospect II 14 Fibrospect II 15 Fibrospect II 16 Fibrospect II 17 Fibrospect II 18 Fibrospect II 18 Fibrospect II 19 Fibrospect II 10 Fibrospect II 10 Fibrospect II 10 Fibrospect II 10 Fibrospect II 11 Fibrospect II 11 Fibrospect II 12 Fibrospect II 12 Fibrospect II 12 Fibrospect II 13 Fibrospect II 14 Fibrospect II 15 Fibrospect II 15 Fibrospect II 16 Fibrospect	11	Eye Culture						
12 Fish for Angiosarcoma MYC Amplification 5 Flow Cytometry for Myeloma 5 Hemoglobinopathy Evaluation 12 Histoplasma Antigen by EIA, Body Fluid 12 Histoplasma Antigen by EIA, Serum 16 Histoplasma Capsulatum Antigen 13 HIV-2 RNA, Qual TMA 13 HIV-2 RNA, Qual TMA 14 HIV-2 RNA, Qual TMA 15 HIV-2 RASA, Confirmation 16 HIV-2 Rig Abs, Confirmation 17 HIV-2 Rig Abs, Confirmation 18 HIV-2 Rig Abs, Confirmation 19 HIV-2 Rig Abs, Confirmation 19 HIV-2 Rig Abs, Confirmation 10 HIV-2 Rig Abs, Confirmation 10 HIV-2 Rig Abs, Confirmation 10 HIV-2 Rig Abs, Confirmation 11 HIV-2 Rig Abs, Confirmation 11 HIV-2 Rig Abs, Confirmation 12 HIV-2 Rig Abs, Confirmation 13 HIV-2 Rig Abs, Confirmation 14 HIV-2 Rig Abs, Confirmation 15 HIV-2 Rig Abs, Confirmation 16 HIV-2 Rig Abs, Confirmation 17 Liggs Subclass (IGC34) 18 Rig Subclass (IGC34) 19 Rig Subclass (IGC34) 10 Rig Subclass (IGC34) 11 Rig Subclass (IGC34) 11 Rig Subclass (IGC34) 11 Rig Subclass (IGC34) 12 Rig Subclass (IGC34) 13 MRSAS/taph Aureus Culture Screen 14 Mucin 15 Neurofibromatoris Type 1, Comprehensive 16 Neurofibromatoris Type 1, Comprehensive 17 Ova and Parasite Exam 18 OvA1 19 Plasminogen Activator Inhibitor 19 PRO-Predicit? TPMT 19 Protein Electrophoresis, Fluid 10 Protein Electrophoresis, Fluid 11 Reducing Substances, Urine 16 Respiratory Synctia Virus Abs IgG and IgM 17, 18 Nature Body Fluid Analysis 13 Sinus Culture and Stain	11	Eye Culture and Stain						
12 FISH for Anglosarcoma MYC Amplification 5 Flow Cytometry for Myeloma 1 Henoglobinopathy Evaluation 1 Histoplasma Antigen by EIA, Body Fluid 1 Histoplasma Antigen by EIA, Sarum 1 Histoplasma Antigen by EIA, Sarum 1 Histoplasma Capsulatum Antigen 1 HIV.2 NRA, Qual TMA 1 HIV.2 Antibody Confirmation, Sarum 1 HIV.2 IgG Abs, Confirmation 2 HiV.2 IgG Abs, Confirmation 3 HIV.2 IgG Abs, Confirmation 4 HIV.2 IgG Subclass (IGGSUB) 5 IgG Subclass (IGGSUB) 6 IgG Subclass (IGGSUB) 7 Immunoglobins, Fluid 8 Immunoglobins, Fluid 8 Immunoglobins, Fluid 9 Immun	5	Fentanyl and Metabolite, Urine						
5 Flow Cytometry for Myeloma 5 Hemoglobinopathy Evaluation 12 Histoplasma Antigen by EIA, Body Fluid 13 HIV-1 RNA, Qual TMA 14 Hiv-1 RNA, Qual TMA 15 HIV-2 Antibody Confirmation, Serum 16 HIV-2 RgA bas, Confirmation 17 HIV-2 Antibody Confirmation 18 HIV-2 RgA bas, Confirmation 19 HIV-2 RgA bas, Confirmation 10 HIV-2 IgG Abs, Confirmation 10 HIV-2 IgG Abs, Confirmation 11 HIV-2 RgA bas, Confirmation 12 IgG Subclass (IGG1234) 13 IgG Subclass (IGG34) 14 IgG Subclass (IGG44) 15 IgG Subclass (IGG44) 16 IgG Subclass (IGG44) 16 Igg Subclass (IGG5UB) 16 Immunoglobins, Fluid 16 Immunoglobins, Fluid 17 Immunoglobins, Urine 18 Inhibin B 19 Inner Far 68KD Ab 19 Inner Far 68KD Ab 10 Legionella Antibodies 10 Leukocyte Alkaline Phosphatase Stain 10 Monoclonal Protein, Fluid 11 MRSA/Staph Aureus Culture Screen 11 Mucin 12 MRSA/Staph Aureus Culture Screen 13 MRSA/Staph Aureus Culture Screen 14 Mucin 15 Neurofibromatosis Type 1, Comprehensive 16 Neurofibromatosis Type 1, Comprehensive 17 Ova and Parasite Exam 18 Ova Il 19 Protein Electrophonesis, Fluid 19 Protein Electrophonesis, Fluid 19 Proteinses 3 Autoantibodies 10 Reducing Substances, Urine 10 Respiratory Synctial Virus Abbs IgG and IgM 17, 15 Routine Body Fluid Analysis 10 Sinus Culture and Stain	12	Fibrospect II						
5 Hemoglobinopathy Evaluation 12 Histoplasma Antigen by EIA, Body Fluid 12 Histoplasma Antigen by EIA, Serum 13 HIV-1 RNA, Qual TMA 13 HIV-2 RNA, Qual TMA 14 HIV-2 RNA, Qual TMA 15 HIV-2 gG Abs, Confirmation, Serum 16 HIV-2 gG Abs, Confirmation 17 HIV-2 IgG Abs, Confirmation 18 HIV-2 RMA, Qual TMA 19 HIV-2 IgG Abs, Confirmation 19 HIV-2 IgG Abs, Confirmation 10 IgG Subclass (IGG-234) 10 IgG Subclass (IGG-34) 10 IgG Subclass (IGG-34) 11 Immunoglobins, Fluid 11 Immunoglobins, Fluid 12 Immunoglobins, Fluid 13 Immunoglobins, Fluid 14 Immunoglobins, Fluid 15 Inner Ear 68KD Ab 16 Legionella Antibodies 16 Leukocyte Alkaline Phosphatase Stain 16 Monoclonal Protein, Fluid 17 MRSA/Staph Aureus Culture Screen 18 Mucin 19 Neurofibromatosis Type I, Comprehensive 10 Neurofibromatosis Type I, Comprehensive 11 Neurofibromatosis Type I, Comprehensive 12 Neurofibromatosis Type I, Comprehensive 13 OVA1 14 Plasminogen Activator Inhibitor 15 Proteinses 3 Autoantibodies 16 Reducing Substances, Urine 17 Proteinses 3 Autoantibodies 18 Reducing Substances, Urine 19 Reducing Substances, Urine 19 Simus Culture and Stain	12	FISH for Angiosarcoma MYC Amplification						
12 Histoplasma Antigen by EIA, Body Fluid 12 Histoplasma Capsulatum Antigen 13 HIV-1 RNA, Qual TIMA 13 HIV-2 Antibody Confirmation, Serum 16 HIV-2 IgG Abs, Confirmation 17 HIV-2 IgG Abs, Confirmation 18 HIV-2 Antibody Confirmation 19 HIV-2 IgG Abs, Confirmation 19 HIV-2 IgG Abs, Confirmation 10 HIV-2 IgG Abs, Confirmation 10 HIV-2 IgG Abs, Confirmation 11 IgG Subclass (IGG24) 11 IgG Subclass (IGG34) 12 IgG Subclass (IGG34) 13 IgG Subclass (IGG40) 14 Igg Subclass (IGG5UB) 15 Immunoglobins, Fluid 16 Immunoglobins, Urine 16 Inhibib B 16 Inner Ear 68KD Ab 16 Legionella Antibodies 16 Leukocyte Alkaline Phosphatase Stain 17 IgG Alkaline Phosphatase Stain 18 IgG Alkaline Phosphatase Stain 19 IgG Alkaline Phosphatase Stain 19 IgG Alkaline Phosphatase Stain 20 IgG Alkaline Phosphatase Stain 21 IgG Alkaline Phosphatase Stain 22 IgG Alkaline Phosphatase Stain 23 IgG Alkaline Phosphatase Stain 24 IgG Alkaline Phosphatase Stain 25 IgG Alkaline Phosphatase Stain 26 IgG Alkaline Phosphatase Stain 27 IgG Alkaline Phosphatase Stain 28 IgG Alkaline Phosphatase Stain 29 IgG Alkaline Phosphatase Stain 30 IgG Alkaline Phosphatase Stain 31 Ova and Parasite Exem 42 IgG Alkaline Phosphatase Stain 43 IgG Alkaline Phosphatase Stain 44 IgG Alkaline Phosphatase Stain 45 IgG Alkaline Phosphatase Stain 46 IgG Alkaline Phosphatase Stain 47 Ova and Parasite Exem 48 IgG Alkaline Phosphatase Stain 49 IgG Alkaline Phosphatase Stain 40 IgG Alkaline Phosphatase Stain 41 IgG Alkaline Phosphatase Stain 41 IgG Alkaline Phosphatase Stain 42 IgG Alkaline Phosphatase Stain 45 IgG Alkaline Phosphatase Stain 46 IgG Subclass IgG Alkaline Phosphatase Phosph	5	Flow Cytometry for Myeloma						
12 Histoplasma Antigen by EIA, Serum 16 Histoplasma Capsulatum Antigen 17 HiV-1 RNA, Qual TMA 18 HiV-2 Antibody Confirmation, Serum 18 HiV-2 Indibody Confirmation, Serum 19 HiV-2 Indibody Confirmation 20 HiV-2 IgG Abs, Confirmation 30 HiV-2 IgG Abs, Confirmation 41 HiV-2 IgG Abs, Confirmation 42 IgG Subclass (IG1234) 43 IgG Subclass (IG1234) 44 IgG Subclass (IGGSUB) 45 IgG Subclass (IGGSUB) 46 IgG Subclass (IGGSUB) 47 Immunoglobins, Fluid 48 Immunoglobins, Fluid 49 Inmunoglobins, Urine 40 Inhibin B 40 Inner Ear 68KD Ab 41 Legionella Antibodies 41 Legionella Antibodies 42 Leukocyte Alkaline Phosphatase Stain 43 MRSA/Staph Aureus Culture Screen 44 Mucin 45 Mucin 46 Neurofibromatosis Type 1, Comprehensive 47 Ova and Parasite Exam 48 Ova and Parasite Exam 59 Ova and Parasite Screen 51 OVA1 50 PRO-Predict TPMT 50 Proteinase 3 Autoantibodies 51 Reducing Substances, Urine 51 Respiratory Synctial Virus Abs IgG and IgM 51 Neurofibro Sirus Both Fuld Analysis 51 Sinus Culture and Stain	5	Hemoglobinopathy Evaluation						
16 Histoplasma Capsulatum Antigen 13 HIV-2 RNA, Qual TMA 16 HIV-2 IgG Abs, Confirmation, Serum 16 HIV-2 IgG Abs, Confirmation 6 HLA-827 6 IDH1 and IDH2 Mutation Analysis, Exon 4 6 IgG Subclass (IGG34) 6 IgG Subclass (IGG4) 7 Immunoglobins, Fluid 8 Immunoglobins, Fluid 9 Inmunoglobins, Fluid 9 Inhibin B 9 Inner Ear 68KD Ab 9	12	Histoplasma Antigen by EIA, Body Fluid						
13       HIV-1 RNA, Qual TMA         13       HIV-2 Antibody Confirmation, Serum         16       HIV-2 IgG Abs, Confirmation         6       HLA-B27         6       IDH1 and IDH2 Mutation Analysis, Exon 4         6       IgG Subclass (IG1234)         6       IgG Subclass (IGSUB)         16       Ing Subclass (IGSUB)         16       Immunoglobins, Fluid         16       Immunoglobins, Urine         6       Inhibin B         6       Inhibin B         6       Iner Er GBKD Ab         16       Legionella Antibodies         6       Leukocyte Alkaline Phosphatase Stain         13       MRSA/Staph Aureus Culture Screen         6       Mucin         6       Neurofibromatosis Type 1, Comprehensive         6       Neurofibromatosis Type 1, Comprehensive         6       Neurofibromatosis Type 1, Comprehensive         6       Neurophil Cytoplasmic Antibody         7       Ova and Parasite Exam         7       Ova and Parasite Exam         13       OVA1         7       PRO-PredicIR TPMT         16       Protein Electrophoresis, Fluid         7       Proteinase 3 Autoantibodies	12	Histoplasma Antigen by EIA, Serum						
13 HIV-2 Antibody Confirmation, Serum 16 HIV-2 IgG Abs, Confirmation 6 HIA-B27 6 IDH1 and IDH2 Mutation Analysis, Exon 4 6 IgG Subclass (IG1234) 6 IgG Subclass (IGGSUB) 6 Ilg Subclass (IGGSUB) 7 Immunoglobins, Fluid 8 Inmunoglobins, Urine 9 Inmunoglobins, Urine 9 Inhibin B 9 Inner Ear 68KD Ab 9 Icgolaella Antibodies 9 Icgolaella Antibodies 9 Icgolaella Antibodies 9 Icgolaella Antibodies 10 Inner Ear 68KD Ab 11 Legionella Antibodies 12 Icgolaella Antibodies 13 MRSA/Staph Aureus Culture Screen 14 Nucin 15 Neurofibromatosis Type 1, Comprehensive 16 Neurofibromatosis Type 1, Comprehensive 17 Ova and Parasite Exam 18 OVA1 19 Plasminogen Activator Inhibitor 19 PRO-PredictR TPMT 10 Protein Electrophoresis, Fluid 10 Respiratory Synctial Virus Abs IgG and IgM 11 Sinus Culture and Stain	16	Histoplasma Capsulatum Antigen						
16 HIV-2 IgG Abs, Confirmation 6 HLA-B27 6 IDH1 and IDH2 Mutation Analysis, Exon 4 6 IgG Subclass (IG1234) 6 IgG Subclass (IGG4) 6 IgG Subclass (IGGSUB) 16 Immunoglobins, Fluid 17 Immunoglobins, Fluid 18 Immunoglobins, Urine 19 Inmunoglobins, Urine 10 Inmunoglobins, Urine 11 Immunoglobins, Urine 12 Inmunoglobins, Urine 13 Inmunoglobins, Urine 14 Inmunoglobins, Urine 15 Inmunoglobins, Urine 16 Inthibin B 17 Inmunoglobins, Urine 18 Inmunoglobins, Urine 19 Inmunoglobins, Urine 10 Inmunoglobins, Urine 11 Inmunoglobins, Urine 11 Inmunoglobins, Urine 11 Inmunoglobins, Urine 12 Inmunoglobins, Urine 13 Inmunoglobins, Urine 14 Inmunoglobins, Urine 15 Inmunoglobins, Urine 16 Inmunoglobins, Urine 17 Monoclopal Protein, Fluid 18 Inmunoglobins, Urine 19 Inmunoglobins, Urine 10 Neurophi Oytoplasmic Antibody 10 Va and Parasite Exam 11 OVA1 12 Inmunoglobins, Urine 13 Reducing Subtances, Urine 14 Respiratory Synctial Virus Abs IgG and IgM 17, 15 Routine Body Fluid Analysis 18 Sinus Culture and Stain	13	HIV-1 RNA, Qual TMA						
6 HLA-B27 6 IDH1 and IDH2 Mutation Analysis, Exon 4 6 IgG Subclass (IG1234) 6 IgG Subclass (IGG4) 6 IgG Subclass (IGGSUB) 16 Immunoglobins, Fluid 17 Immunoglobins, Fluid 18 Immunoglobins, Urine 19 Inhibin B 10 Inner Ear 68KD Ab 11 Leglonella Antibodies 11 Leglonella Antibodies 12 Leukocyte Alkaline Phosphatase Stain 13 MRSA/Staph Aureus Culture Screen 14 Mucin 15 Meurofibromatosis Type 1, Comprehensive 16 Neutrophil Cytoplasmic Antibody 17 Ova and Parasite Exam 18 Ova and Parasite Screen 19 Ova 19 PRO-PredictR TPMT 19 PRO-PredictR TPMT 10 Protein Electrophoresis, Fluid 17 Proteinses 3 Autoantibodies 18 Reducing Substances, Urine 19 Reducing Substances, Urine 10 Respiratory Synctial Virus Abs IgG and IgM 19 Routine Body Fluid Analysis 10 Sinus Culture and Stain	13	HIV-2 Antibody Confirmation, Serum						
6 IDH1 and IDH2 Mutation Analysis, Exon 4 6 IgG Subclass (IG1234) 6 IgG Subclass (IGG4) 6 IgG Subclass (IGGSUB) 16 Immunoglobins, Fluid 16 Immunoglobins, Urine 6 Inhibin B 6 Inner Ear 68KD Ab 16 Legionella Antibodies 16 Leukocyte Alkaline Phosphatase Stain 16 Monoclonal Protein, Fluid 17 MRSA/Staph Aureus Culture Screen 18 Mucin 19 Neurofibromatosis Type 1, Comprehensive 19 Neurofibromatosis Type 1, Comprehensive 20 Neurophil Cytoplasmic Antibody 21 Ova and Parasite Exam 22 Ova and Parasite Exam 23 OvA1 24 Plasminogen Activator Inhibitor 25 PRO-PredictR TPMT 26 Protein Electrophoresis, Fluid 26 Respiratory Synctial Virus Abs IgG and IgM 27 Routine Body Fluid Analysis 28 Sinus Culture and Stain	16	HIV-2 IgG Abs, Confirmation						
6 IgG Subclass (IG1234) 6 IgG Subclass (IGG4) 6 IgG Subclass (IGGSUB) 16 Immunoglobins, Fluid 16 Immunoglobins, Urine 6 Inhibin B 6 Inner Ear 68KD Ab 16 Legionella Antibodies 16 Leukocyte Alkaline Phosphatase Stain 16 Monoclonal Protein, Fluid 13 MRSA/Staph Aureus Culture Screen 6 Mucin 6 Neurofibromatosis Type 1, Comprehensive 6 Neutrophil Cytoplasmic Antibody 7 Ova and Parasite Exam 7 Ova and Parasite Screen 13 OVA1 7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7, 15 Reducing Substances, Urine 18 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	6	HLA-B27						
6 IgG Subclass (IGG4) 6 IgG Subclass (IGGSUB) 16 Immunoglobins, Fluid 16 Immunoglobins, Fluid 17 Immunoglobins, Fluid 18 Immunoglobins, Fluid 19 Inner Ear 68KD Ab 19 Inner Ear 68KD Ab 10 Legionella Antibodies 10 Leukocyte Alkaline Phosphatase Stain 11 Monoclonal Protein, Fluid 11 MRSA/Staph Aureus Culture Screen 12 Mucin 13 MRSA/Staph Aureus Culture Screen 14 Neurofibromatosis Type 1, Comprehensive 15 Neurofibromatosis Type 1, Comprehensive 16 Neurofibromatosis Type 1, Comprehensive 17 Ova and Parasite Exam 18 OVA1 19 Plasminogen Activator Inhibitor 19 PRO-PredictR TPMT 10 Protein Electrophoresis, Fluid 10 Respiratory Synctial Virus Abs IgG and IgM 10 Respiratory Synctial Virus Abs IgG and IgM 10 Respiratory Synctial Virus Abs IgG and IgM 11 Sinus Culture and Stain	6	IDH1 and IDH2 Mutation Analysis, Exon 4						
6 IgG Subclass (IGGSUB) 16 Immunoglobins, Fluid 16 Immunoglobins, Urine 6 Inhibin B 6 Inner Ear 68KD Ab 16 Legionella Antibodies 6 Leukocyte Alkaline Phosphatase Stain 16 Monoclonal Protein, Fluid 13 MRSA/Staph Aureus Culture Screen 6 Mucin 6 Neurofibromatosis Type 1, Comprehensive 6 Neutrophil Cytoplasmic Antibody 7 Ova and Parasite Exam 7 Ova and Parasite Screen 13 OVA1 7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	6	IgG Subclass (IG1234)						
Inmunoglobins, Fluid Immunoglobins, Urine Inhibin B Inner Ear 68KD Ab Inner Ear 68KD	6	IgG Subclass (IGG4)						
16 Immunoglobins, Urine 6 Inhibin B 6 Inner Ear 68KD Ab 16 Legionella Antibodies 6 Leukocyte Alkaline Phosphatase Stain 16 Monoclonal Protein, Fluid 13 MRSA/Staph Aureus Culture Screen 6 Mucin 6 Neurofibromatosis Type 1, Comprehensive 6 Neutrophil Cytoplasmic Antibody 7 Ova and Parasite Exam 7 Ova and Parasite Exam 8 OVA1 9 Plasminogen Activator Inhibitor 9 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	6	IgG Subclass (IGGSUB)						
6 Inhibin B 6 Inner Ear 68KD Ab 16 Legionella Antibodies 6 Leukocyte Alkaline Phosphatase Stain 16 Monoclonal Protein, Fluid 13 MRSA/Staph Aureus Culture Screen 6 Mucin 6 Neurofibromatosis Type 1, Comprehensive 6 Neutrophil Cytoplasmic Antibody 7 Ova and Parasite Exam 9 Ova and Parasite Screen 13 OVA1 7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	16	Immunoglobins, Fluid						
6 Inner Ear 68KD Ab 16 Legionella Antibodies 6 Leukocyte Alkaline Phosphatase Stain 16 Monoclonal Protein, Fluid 13 MRSA/Staph Aureus Culture Screen 6 Mucin 6 Neurofibromatosis Type 1, Comprehensive 6 Neutrophil Cytoplasmic Antibody 7 Ova and Parasite Exam 7 Ova and Parasite Screen 13 OVA1 7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	16	Immunoglobins, Urine						
16 Legionella Antibodies 6 Leukocyte Alkaline Phosphatase Stain 16 Monoclonal Protein, Fluid 13 MRSA/Staph Aureus Culture Screen 6 Mucin 6 Neurofibromatosis Type 1, Comprehensive 6 Neutrophil Cytoplasmic Antibody 7 Ova and Parasite Exam 7 Ova and Parasite Screen 13 OVA1 7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	6	Inhibin B						
6 Leukocyte Alkaline Phosphatase Stain 16 Monoclonal Protein, Fluid 13 MRSA/Staph Aureus Culture Screen 6 Mucin 6 Neurofibromatosis Type 1, Comprehensive 6 Neutrophil Cytoplasmic Antibody 7 Ova and Parasite Exam 7 Ova and Parasite Screen 13 OVA1 7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	6	Inner Ear 68KD Ab						
16 Monoclonal Protein, Fluid 13 MRSA/Staph Aureus Culture Screen 6 Mucin 6 Neurofibromatosis Type 1, Comprehensive 6 Neutrophil Cytoplasmic Antibody 7 Ova and Parasite Exam 7 Ova and Parasite Screen 13 OVA1 7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	16	Legionella Antibodies						
13 MRSA/Staph Aureus Culture Screen 6 Mucin 6 Neurofibromatosis Type 1, Comprehensive 6 Neutrophil Cytoplasmic Antibody 7 Ova and Parasite Exam 7 Ova and Parasite Screen 13 OVA1 7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	6	Leukocyte Alkaline Phosphatase Stain						
6 Neurofibromatosis Type 1, Comprehensive 6 Neutrophil Cytoplasmic Antibody 7 Ova and Parasite Exam 7 Ova and Parasite Screen 13 OVA1 7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	16	Monoclonal Protein, Fluid						
6 Neutrophil Cytoplasmic Antibody 7 Ova and Parasite Exam 7 Ova and Parasite Screen 13 OVA1 7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	13	MRSA/Staph Aureus Culture Screen						
6 Neutrophil Cytoplasmic Antibody 7 Ova and Parasite Exam 7 Ova and Parasite Screen 13 OVA1 7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	6	Mucin						
7 Ova and Parasite Exam 7 Ova and Parasite Screen 13 OVA1 7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	6	Neurofibromatosis Type 1, Comprehensive						
7 Ova and Parasite Screen  13 OVA1  7 Plasminogen Activator Inhibitor  7 PRO-PredictR TPMT  16 Protein Electrophoresis, Fluid  7 Proteinase 3 Autoantibodies  13 Reducing Substances, Urine  16 Respiratory Synctial Virus Abs IgG and IgM  7, 15 Routine Body Fluid Analysis  13 Sinus Culture and Stain	6	Neutrophil Cytoplasmic Antibody						
13 OVA1 7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	7	Ova and Parasite Exam						
7 Plasminogen Activator Inhibitor 7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	7	Ova and Parasite Screen						
7 PRO-PredictR TPMT 16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	13	OVA1						
16 Protein Electrophoresis, Fluid 7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	7	Plasminogen Activator Inhibitor						
7 Proteinase 3 Autoantibodies 13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM 7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	7	PRO-PredictR TPMT						
13 Reducing Substances, Urine 16 Respiratory Synctial Virus Abs IgG and IgM  7, 15 Routine Body Fluid Analysis 13 Sinus Culture and Stain	16	Protein Electrophoresis, Fluid						
16 Respiratory Synctial Virus Abs IgG and IgM  7, 15 Routine Body Fluid Analysis  13 Sinus Culture and Stain	7	Proteinase 3 Autoantibodies						
7, 15 Routine Body Fluid Analysis  13 Sinus Culture and Stain	13	Reducing Substances, Urine						
7, 15 Routine Body Fluid Analysis  13 Sinus Culture and Stain	16	Respiratory Synctial Virus Abs IgG and IgM						
13 Sinus Culture and Stain	7, 15							
	7							



#### Test Changes

Test Name	Order Code	Billing Code	Change	Effective Date
5-Fluorouracil (5-FU) Toxicity, Chemotherapeutic Response, <b>5</b> Mutations	5FLUO	89425	Name: 5-Fluorouracil (5-FU) Toxicity, Chemotherapeutic Response, 5 Mutations.  Components:  Tox,Response-DPYD c.1679T>G Tox,Response-DPYD c.2846A>T Tox,Response-DPYD c.1905+1G>A Tox,Response-TYMS 3'UTR Genotype Tox,Response-TYMS 5'TSER Genotype Clinical Info: Clinical Sensitivity and Specificity: Estimated at 31 percent for the DYPD variants analyzed. Analytical Sensitivity and Specificity: 99%. Useful for evaluating toxicity and tumor response in patients receiving 5-fluorouracil or capecitabine treatment for colorectal adenocarcinoma.	11/17/2014
ACTH Stimulation Test for 21 - Hydroxylase	AS21	82059	Reference Ranges: Hydroxyprogest, Basal [Result Code: HPRG0]: Female: 1D: 20-200 ng/dL Female: 1M: 30-110 ng/dL Female: 7M: 10-50 ng/dL Female: 7y: 0-50 ng/dL Female: 1y: 0-50 ng/dL Female: 7y: 0-40 ng/dL Female: 7y: 0-40 ng/dL Female: 10y: 0-30 ng/dL Female: 13y: 0-70 ng/dL Female: 10y: 0-90 ng/dL Male: 1D: 50-190 ng/dL Male: 1D: 50-190 ng/dL Male: 1M: 40-160 ng/dL Male: 7y: 0-20 ng/dL Male: 4y: 0-30 ng/dL Male: 4y: 0-30 ng/dL Male: 4y: 0-30 ng/dL Male: 10y: 0-50 ng/dL Male: 10y: 0-50 ng/dL Male: 10y: 0-50 ng/dL Male: 19y: 0-50 ng/dL Male: 19y: 0-50 ng/dL Male: 19y: 40-180 ng/dL Male: 19y: 40-180 ng/dL Hydroxyprogest, 60 min [Result Code: HPRG60]: 0-99 Years: 0 ng/dL	9/3/2014

Test Name	Order Code	Billing Code	Change	Effective Date
Allergen, Respiratory Region 8	RESPR8	90027	Components: Hickory/ Pecan Tree	9/30/2014
Amitriptyline/Nortriptyline	AMINOR	82138	Reference Range: Urgent Range - 0-99 years: >500 ng/mL	11/5/2014
Buprenorphine, Quant Urine	UQNTBU	89916	Add component(s): Quantitative Pain Panel, Urine - Creatinine, Oxidants, pH, Specific Gravity.	10/20/2014
Catecholamines, Fract. Plasma	PLCAT	41000	Specimen Volume: 3.0 mL (2.3 mL minimum)	9/2/2014
Catecholamines, Fract. Tilt	TPLCAT	81728	Specimen Volume: 3.0 mL (2.3 mL minimum)	9/2/2014
Chromagranin A	CHROMA	76178	Reported: 4-7 Days	11/20/2014
CMV PCR, Bone Marrow	CMVBM	89659	Specimen Requirements: 1.0 mL Bone marrow - EDTA (Lavender - 0.5 mL minimum); Refrigerated.  Methodology: Qualitative Polymerase Chain Reaction  Clinical Info: Detects cytomegalovirus in bone marrow but does not quantify viral load.  Days Performed: Sunday-Saturday  Stability:  Refrigerated: 72 Hours Frozen: Unacceptable Ambient: 8 Hours	10/2/2014
Cryptosporidia Examination	CRYSPO	89919	Clinical Info: The Cryptosporidium test uses microscopic staining methods (Modified Acid Fast) to rule out infection due to Cryptosporidium, Cyclospora and Cystoisospora sp. in stool. Infection with these agents generally occurs through ingestion of contaminated water or food and causes diarrhea. Immunocompromised patients are more susceptible to infection. One negative result does not rule out the possibility of infection.  Days Performed: Monday-Friday  Reported: 1-7 Days  Alias: Cystoisopora Examination	10/9/2014
Cyto P450 2C19 Genotype	2C19PL	88307	Specimen Requirements: 3.0 mL Whole blood - EDTA (Lavender - 1.0 mL minimum); Refrigerated.  Alternate - 3.0 mL Whole blood ACD A or B (Yellow - 1.0 mL minimum); Refrigerated.  Special Info: May aid in dose planning for clopidogrel and other drugs metabolized by CYP2C19.  Component(s): CYP2C19, Variant 1, CYP2C19 Variant 2, CYP2C19  Predicted Phenotype  Methodology: Polymerase Chain Reaction (PCR)  Clinical Info: Background Information for Cytochrome P450 2C19  (CYP2C19) 9 Variants: Characteristics: Impaired drug metabolism causing adverse drug reactions or lack of drug response. Drugs metabolized by CYP2C19 include clopidogrel, S-mephenytoin, diazepam, R-warfarin, some antidepressants (eg, citalopram, amitriptyline, clomipramine), proton pump inhibitors (eg, omeprazole, lansoprazole), and antimalarials (eg, chloroguanide). Inheritance: Autosomal recessive. Cause: CYP2C19 allelic variants. Negative: No variants detected is predictive of *1 functional alleles and normal enzymatic activity. Variants Tested: (Variants are numbered according to NM_000769 transcript). Decreased function: *9 (c.431G>A); *10 (c.680C>T). Non-functional: *2 (c.681G>A), *3 (c.636G>A), *4 (c.1A>G), *6 (c.395G>A), *7 (c.819+2T>A), *8 (c.358T>C). Increased function: *17 (c806C>T; increased gene transcription). Incidence of Poor Metabolizer Phenotype: 4 percent of Caucasians, 5 percent of African Americans, and up to 25 percent of Asians. Penetrance: Drug dependent. Clinical Sensitivity: 99 and 87 percent of clinically significant variants detected in Asians and Caucasians respectively; sensitivity is unknown in other ethnicities. Analytical Sensitivity and Specificity: 99 percent. Limitations: Only the targeted CYP2C19 variants will be detected. Variants in other genes will not be detected. Diagnostic errors can occur due to rare sequence variations. Variant detection is not a substitute for therapeutic drug monitoring or other clinical monitoring.  Days Performed: Monday, Thursday Reported: 8-16 Days	10/30/2014

9500 Euclid Avenue | Cleveland, Ohio 44195 | 216.444.5755 | 800.628.6816 | clevelandcliniclabs.com

Test Name	Order Code	Billing Code	Change	Effective Date
Cyto P450 2D6 Geno	2D6	87628	Specimen Requirements: 3.0 mL Whole blood - EDTA (Lavender - 1.0 mL minimum); Refrigerated.  Alternate - 3.0 mL Whole blood ACD A or B (Yellow - 1.0 mL minimum); Refrigerated.	10/30/2014
			Special Info: May aid in dose planning for tamoxifen and other drugs metabolized by CYP2D6.  Component(s): CYP2D6 Variant 1, CYP2D6 Variant 2, CYP2D6 Variant 3, CYP2D6 Variant 4, 2D6 Predicted Phenotype.	
			Clinical Info: Background Information for Cytochrome P450 2D6 (CYP2D6) 14 Variants and Gene Duplication: Characteristics: Impaired drug metabolism causing adverse drug reactions or lack of drug response. Drugs metabolized by CYP2D6 include antiestrogens (tamoxifen), alpha-blockers, analgesics, anticonvulsives, antidepressants, antidiabetics, antihypertensives, antipsychotics, antitussives, beta blockers, cardioactives, norepinephrine reuptake inhibitors, and stimulants. Additionally, many drugs inhibit CYP2D6 activity, and may affect drug response. Inheritance: Autosomal recessive. Cause: CYP2D6 gene variants. Negative: No mutations detected is predictive of *1 functional alleles. Variants Tested: (Variants are numbered according to M33388 sequence.) Functional: *2 (2850C>T), *2A (-1584C>G; 2850C>T). Decreased function: *9 (2613-5delAGA), *10 (100C>T), *17 (1023C>T), *29 (1659G>A) *41 (2988G>A). Non-functional: *3 (2549delA), *4 (1846G>A), *5 (gene deletion), *6 (1707delT), *7 (2935A>C), *8 (1758G>T), *12 (124G>A), *14 (1758G>A). Increased function: Duplicated functional alleles. Incidence of Poor Metabolizer Phenotype: 10 percent of Caucasians and Hispanics, 2 percent of African Americans, and 1 percent of Asians. Penetrance: Drug dependent. Clinical Sensitivity: Greater than 95 percent of clinically significant CYP2D6 variants are detected in Caucasians; sensitivity is unknown in other ethnicities.  Methodology: Multiplex polymerase chain reaction and detection primer extension. Analytical Sensitivity and Specificity: Greater than 99 percent for the variants tested. Limitations: Only the targeted CYP2D6 variants will be detected. Variants in other genes will not be detected. Diagnostic errors can occur due to rare sequence variations. Variant detection is not a substitute for therapeutic drug monitoring or other clinical monitoring. Days Performed: Monday, Thursday  Reported: 8-16 Days  CPT: 81226x1  Price: \$828.00	
Fentanyl and Metabolite, Urine	UFENT	82344	Specimen Requirements: 10.0 mL Random urine in a clean container (2.5 mL minimum)  Components: Fentanyl, Norfentanyl, Creatinine, pH, Specific Gravity, Oxidants.  Reference Ranges: Fentanyl, Urine <6 ng/mL Norfentanyl, Urine <6 ng/mL Creatinine, Urine: >19 mg/dL Urine pH: 4-10 Urine Specific Gravity: 1.005 – 1.020 Oxidants, Urine: Negative Methodology: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Days Performed: 4 days per week Reported: 2-5 Days	10/20/2014
Flow Cytometry for Myeloma	FCMYEL	82848	Special Info: Includes: CD45- CD38+ cells; CD45- CD38+ Kappa+ cells; CD45- CD38+ Lambda+ cells; CD45- CD38+ CD19+ cells; CD45- CD138+ cells; CD45- CD138+ CD19+ cells; CD45- CD138+ Lambda+ cells; CD45- CD138+ CD19+ cells; CD56. Submit tissue specimen or fine needle aspirate with Surgical Pathology requisition.  CPT: 88187x1, 88185x6, 88184x1	10/2/2014
Hemoglobinopathy Evaluation	HBHPLC	84444	<b>Special Info:</b> Indicate age of patient, and/or ethnic background and date of most recent blood transfusion. If an abnormal hemoglobin or abnormal distribution of hemoglobins is found, additional hemoglobin studies will be performed and charged separately. These tests include alkaline and acid electrophoresis, sickle solubility, globin chain electrophoresis, Hb H stain, unstable hemoglobin and <b>ferritin</b> .	10/2/2014

Test Name	Order Code	Billing Code	Change	Effective Date
HLA-B27	HLAB27	77024	Specimen Requirements: Draw specimens Monday through Thursday only. DO NOT draw on Fridays, weekends, or holidays.	10/1/2014
IDH1 and IDH2 Mutation Analysis, Exon 4	IDH12	88044	Specimen Requirements: 5.0 mL Whole blood - EDTA (Lavender - 1.0 mL minimum); Refrigerated. 3.0 mL Bone marrow - EDTA (Lavender - 1.0 mL minimum); Refrigerated. 4 Unstained 5-micron thick slides (3 slides minimum); Ambient. 1 Formalin-fixed paraffin Block; Refrigerated. FFPE tumor tissue Formalin fix (10 percent neutral buffered formalin) and paraffin embedded tissue. Extracted DNA - EDTA (Lavender). 20 uL extraced DNA at a concentration of 50 ng/uL is required.	11/20/2014
			Methodology: Polymerase Chain Reaction/Sequencing	
			Reported: 13-16 Days	
			Stability: Ambient - 24 Hours. FFPE tumor tissue: Indefinitely. Refrigered - 5 Days. FFPE tumor tissue: Indefinitely. Frozen - Unacceptable.	
IgG Subclasses	IG1234	82141	Reference Range:  IgG Subclass 1: 18-99 Years: 398-965 mg/dL  IgG Subclass 2: 18-99 Years: 176-698 mg/dL  IgG Subclass 3: 18-99 Years: 16-134 mg/dL  IgG Subclass 4: 18-99 Years: 5-131 mg/dL	10/21/2014
			Days Performed: Monday-Friday	
IgG Subclasses	IGG4	80607	Reference Range: 18-99 Years: 5-131 mg/dL	10/21/2014
			Days Performed: Monday-Friday	
IgG Subclasses	IGGSUB	75776	Reference Range:  IgG Subclass 1: 18-99 Years: 398-965 mg/dL  IgG Subclass 2: 18-99 Years: 176-698 mg/dL  IgG Subclass 3: 18-99 Years: 16-134 mg/dL  IgG Subclass 4: 18-99 Years: 5-131 mg/dL	10/21/2014
			Days Performed: Monday-Friday	
Inhibin B	INHIBB	82819	Reported: 1-7 Days	11/20/2014
Inner Ear 68KD Ab	AB68KD	81984	Stability: Ambient: 4 Days Refrigerated: 7 Days. Frozen: Store frozen at -20°C if not tested within 7 days. May be stored at -20°C for up to one year. Ship frozen.	10/31/2014
Luekocyte Alkaline Phosphatase Stain	LAPSTN	85632	Specimen Requirements: Alternate: 5.0 mL Whole blood - sodium or lithium heparin (Green). Do not draw in a plasma separator tube. Do not collect after 15:00 or on weekends.	9/10/2014
Mucin	SFMUCN	77606	Test Name: Mucin Clot Time, Synovial Fluid	7/24/2014
Neurofibromatosis Type 1, Comprehensive	NFIB1	88611	<b>CPT</b> : 81407x1, 81408x1, 88230x1	11/1/2014
Neutrophil Cytoplasmic Antibody	ANCA	76168	Component names: P-ANCA (MPO) - Myeloperoxidase Ab C-ANCA (PR3) - Proteinase-3 Ab	9/30/2014

Test Name	Order Code	Billing Code	Change	Effective Date
Ova and Parasite Exam	OVAP	75319	Special Info: A minimum of three specimens collected over 3 - 10 days are recommended. Stool should not be contaminated with water or urine. When appropriate, please note the parasite suspected and note the areas to which the patient has traveled on the order. Requests for Ova and Parasite Exam on patients who have been hospitalized for >3 days are not recommended. Parasites are rarely recovered. Stool specimens obtained with a warm saline enema or Fleets phospho-soda are acceptable. Administration of barium, bismuth, metamucil, castor oil, mineral oil, tetracycline therapy or administration of antiamoebic drugs within 1 week prior to testing may interfere with results. In Urine specimens for the diagnosis of schistosomiasis or Filariasis, 24 hr. urine collections are recommended. Random urine collections are acceptable. Random urines >24 hrs. old or 24 hr. urine collections >48 hrs. old will be rejected. Preserved specimens will be rejected. For the diagnosis of Schistosomiasis infection, there is a circadian rhythm in Schistosoma egg excretion with peak excretion occurring around noon. Collection of a midday urine specimen or a 24 hr. collection in a container without preservatives is recommended. Peak excretion occurs between noon and 3 p.m. In patients with hematuria, eggs may be found trapped in the blood and mucus in the terminal portion (last voided portion) of the urine specimen. For the diagnosis of Trichomonas infection, molecular methods are preferred. Recommended order codes are UTRICM (males) and VAGAMD (females). Trichomonas antigen testing is also available for vaginal specimens only (order code TRICHO).	10/9/2014
Ova and Parasite Screen	OVAPSC	89803	Special Info: The Ova and Parasite Screen is a screening test for Giardia lamblia and Cryptosporidium species only. This test replaces the traditional Ova and Parasite Exam. Ideally, fresh stool should be collected and immediately placed into the O-P transport kits which contain 10% formalin as a preservative. Preserved stool should be transported at ambient temperature. Unpreserved stool should not be submitted unless it can be delivered to the laboratory within a few hours in a clean leakproof container. Unpreserved stool should be transported at either ambient or refrigerator temperature but never frozen. Other transport media such as Cary-Blair, MIF or C & S diluted samples may interfere with confirmatory test methods. Interfering substances include barium, bismuth, metamucil, castor oil, mineral oil, or antiamoebic drugs within one week prior to specimen collection. O-P transport kits with collection instructions can be obtained from Client Services or the Outpatient Laboratories.  Alias: Cryptosporidium Antigen, Giardia Antigen  Reported: 1-6 Days	10/9/2014
Plasminogen Activator Inhibitor	PAI	26303	Primary name: "Plasminogen Activator Inhibitor, Activity"	10/30/2014
PRO-PredictR TPMT	PPTMPT	81267	Components: Test build may need to be modified.	9/30/2014
Proteinase 3 Autoantibodies (C-ANCA)	ANCAC	82580	Test Name: Proteinase 3 Autoantibodies  Component name:  C-ANCA (PR3) - Proteinase 3 Ab	9/30/2014
Routine Body Fluid Analysis	ROUBFL	31	Components: Specific gravity removed from panel (new order code)	10/2/2014
Synovial Fluid, Routine Analysis	ROUSYN	30	Components: Specific gravity and Mucin removed from panel (new order code)	10/2/2014
Vitamin A	VITA	84590	Reference Range: Units (mg/L) 0-1 month: 0.18-0.50 mg/L 2-144 months: 0.20-0.50 mg/L 13-17 years: 0.26-0.70 mg/L 18-99 years: 0.30-1.20 mg/L	9/23/2014
Vitamin D2/D3, Serum	D2D3	83283	<b>Specimen Requirments:</b> 1.0 mL Plasma - EDTA (Lavender); Refrigerated. <b>Special Info:</b> Test not recommended for patients $< 1$ year old. Results may be falsely increased due to interfering substance present in patients less than 1 year old.	11/3/2014

Test Name	Order Code	Billing Code	Change	Effective Date
Wafarin Sensitivity Genotype	WARSEN	88301	Specimen Requirements: 3.0 mL Whole blood - EDTA (Lavender - 1.0 mL minimum); Refrigerated.  Alternate - 3.0 mL Whole blood ACD A or B (Yellow - 1.0 mL minimum); Refrigerated.	10/30/2014
			Special Info: Aids in warfarin dosage planning in conjunction with VKORC1 testing.	
			Components(s): CYP2C9 Variant 1, CYP2C9 Predicted Phenotype, CYP2C9 Variant 2	
			Methodology: Polymerase chain reaction (PCR), DNA Probe Hybridization, and Electrochemical Detection.	
			Clinical Info: Background Information for Cytochrome P450 2C9 (CYP2C9) 2 Variants: Characteristics: Some CYP2C9 mutations cause impaired drug metabolism, a major cause of adverse drug reactions or lack of drug response. For example, CYP2C9 variants are associated with slowed clearance and lower dose requirements for warfarin. Inheritance: Autosomal recessive. Cause:CYP2C9 gene variants. Negative: No variants detected is predictive of *1 functional alleles and normal enzymatic activity. Variants Tested: (Variants are numbered according to NM_000771 transcript) Decreased function: *2 (c.430C>T). Non-functional: *3 (c.1075A>C). Allele Frequencies: CYP2C9 *2: Caucasians 0.08-0.13, Asians 0.02-0.06, African Americans less than 0.01. CYP2C9 *3: Caucasians 0.06-0.10, Asians less than 0.01, African Americans 0.01-0.04. Clinical Sensitivity: Greater than 90 percent of clinically significant CYP2C9 variants are detected in Caucasians; sensitivity is unknown in other ethnicities. Analytical Sensitivity and Specificity: 99 percent. Limitations: Only the targeted CYP2C9 variants will be detected. Variants in other genes will not be detected. Diagnostic errors can occur due to rare sequence variations. Variant detection is not a substitute for therapeutic drug monitoring or other clinical monitoring.	
			Days Performed: Monday, Thursday	
			Reported: 6-9 Days	
			<b>CPT:</b> 81227x1, 81355x1	

#### **New Tests**

Test Name	Order Code	Billing Code	Test Information	Effective Date
5-Hydroxyindoleacetic Acid, Urine 24 Hour	UHIAAD	82950	<b>Specimen Requirement:</b> 1.0 mL Urine, 24 hour collect (well mixed) in a clean container; Refrigerated.	10/6/2014
			<b>Methodology:</b> High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)	
			Reference Range: 0.0-8.0 mg/24 hrs	
			Days Performed: 2 days per week	
			Reported: 1-9 Days	
5-Hydroxyindoleacetic Acid, Urine Random	UHIAR2	80049	<b>Specimen Requirement:</b> 1.0 mL Urine, random, clean container (No preservatives - 0.3 mL minimum). Refrigerated.	10/6/2014
			<b>Methodology:</b> High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)	
			Reference Range: Age: 2-10 years; $<$ 12 mg/g CRT 10-99 years; 0-10 mg/g CRT	
			Days Performed: 2 days per week	
			Reported: 1-9 Days	

Test Name	Order Code	Billing Code	Test Information	Effective Date
Alpha-1-Antitrypsin Serum Level and SERPINA1 Targeted Genotyping	A1APG	90332	Specimen Requirement: 1.0 mL Serum - SST or red (Gold - 0.5 mL minimum); Refrigerated.  Alternate - 5.0 mL Whole blood - EDTA (Lavender - 3.0 mL minimum); Refrigerated.  Special Info: AAT performed in Immunopathology. A1ADNA performed in Molecular Pathology.  Methodology: Real-Time PCR, Nephelometry (NEPH)  Days Performed: Thursday  Reported: 7-10 Days  CPT: 82103x1, G0452x1, 81332x1  Price: \$200.00	11/11/2014
Barbiturates Confirmation, Urine	UBARBC	90310	Specimen Requirement: 5.0 mL Random urine in a clean container (3.0 mL minimum); Refrigerated. For confirmation purposes only.  Special Info: This test can only be added to a drug screen which has been performed and confirmation is indicated. Follow chain of custody procedure when appropriate.  Methodology: Gas Chromatography Mass Spectrometry (GCMS)  Clinical Info: To confirm screen.  Days Performed: Sunday-Saturday  Reported: 1-4 Days  CPT: 80102x1  Price: \$95.00	11/13/2014
Body Fluid Culture and Stain	BFCUL	90174	Specimen Requirement: 5.0 mL Bodyfluid in a clean, leakproof container; Ambient. Transfer 5.0 mL (2.0 mL - minimum) aspirate to a sterile tube or container OR body fluid collected in blood culture bottles, accompanied by orginal specimen, if available.  Methodology: Culture, Identification, Gram Stain  Days Performed: Sunday-Saturday  Reported: 7 Days  CPT: 87070x1, 87205x1 - Additional billing is applied for identification and susceptibility testing. CPT codes vary based on methodology  Price: \$69.00	10/1/2014
Bronchoscopy Culture and Stain	BALCSM	90204	Specimen Requirement: Bronchial washing(s), Bronchoscopy specimen(s) in a clean, leakproof container; Refrigerated.  Methodology: Gram Stain, Culture, Identification  Days Performed: Sunday-Saturday  Reported: 7 Days  CPT: 87205x1, 87071x1  Price: \$69.00	10/1/2014
C9orf72 Expansion Assay	C9ORF	90325	Specimen Requirement: 5.0 mL Whole blood - EDTA (Lavender - 2.0 mL minimum); Ambient.  5.0 mL Whole blood - ACD A or B (Yellow - 2.0 mL minimum); Ambient. Extracted DNA - EDTA (Lavender); Ambient. 15 ug extracted DNA at a concentration of 20 ug/mL is required.  Methodology: Repeat-Primed PCR and Fluorescent Fragment-Length Assay Clinical Info: The function of C9orf72 is unknown at this time. Nonetheless, nuclear RNA foci were detected in affected tissues of patients with expanded GGGGCC repeats, suggesting defective RNA processing (Rademakers et al. Nat Rev Neurol 8(8):423-434, 2012). The repeat-primed PCR test is used as a screening method for the presence or absence of a pathogenic GGGGCC hexanucleotide repeat expansion located in the first intron of C9orf72. Of note, this test is not designed to determine the number of GGGGCC repeats in alleles carrying the pathogenic expansion (Warner et al., 1996; Renton, 2011).  Days Performed: Upon Receipt  Reported: 17 Days  CPT: 81479x1  Price: \$250.00	12/11/2014

Test Name	Order Code	Billing Code	Test Information	Effective Date
Catheter Tip Culture	CTCUL	90175	Specimen Requirement: One catheter, clean container; Ambient. Aseptically remove catheter and clip 5 cm of distal tip directly into a sterile container.  Methodology: Culture, Identification  Days Performed: Sunday-Saturday  Reported: 21 Days  CPT: 87070x1  Price: \$46.00	10/1/2014
Clobazam	CLOBAZ	90152	Specimen Requirement: 1.0 mL Plasma sodium-heparin (Green - 0.5 mL minimum); Refrigerated. Plasma gel tube is not acceptable.  Alternate - 1.0 mL Serum from red top ( 0.5 mL minimum); Refrigerated. Plasma gel tube is not acceptable.  Methodology: Liquid Chromatography/Tandem Mass Spectometry (LC/MS/MS)  Days Performed: Sunday-Saturday  Reported: 7 Days  CPT: 80154  Price: \$112.00	10/23/2014
Cystic Fibrosis Respiratory Culture	CFRCUL	90282	Specimen Requirement: Unspecified sputum in a sterile container; Refrigerated, expectorated, or induced. Unspecified throat swab, culturette; Refrigerated.  Methodology: Culture, Identification  Days Performed: Sunday-Saturday  Reported: 7 Days  CPT: 87070x1  Price: \$46.00	10/28/2014
Ear Culture	EARC	90216	Specimen requirement: Unspecified swab(s) (0.1 mL - minimum); Ambient. Drainage on a swab in either Amies or Stuart's bacterial transport medium. Unspecified aspirate(s) in a sterile container (0.1 mL - minimum); Ambient.  Methodology: Culture, Identification  Days Performed: Sunday-Saturday  Reported: 7 Days  CPT: 87070x1  Price: \$46.00	10/2/2014
Ear Culture and Stain	EARCSM	90183	Specimen Requirement: Unspecified swab(s) (0.1 mL - minimum); Ambient. Drainage on a swab in either Amies or Stuart's bacterial transport medium. Unspecified aspirate(s) (0.1 mL - minimum); Ambient. Place in a sterile container with saline.  Methodology: Gram Stain, Culture, Identification  Days Performed: Sunday-Saturday  Reported: 7 Days  CPT: 87205x1, 87070x1  Price: \$69.00	10/1/2014

Test Name	Order Code	Billing Code	Test Information	Effective Date
Eye Culture	EYEC	90200	Specimen Requirement: Place drainage into a sterile container; Ambient. Place fluid into a sterile container with saline; Ambient. Place scrapings in a sterile container; Ambient. Place scraping directly on culture media plates. Media is available through the microbiology laboratory for direct inocuation, particularly for corneal scrapings.	10/1/2014
			Special Info: Media and incubation conditions are employed for the recovery of aerobic bacteria. For conjunctival specimens, sample each eye with separate swabs (pre-moistened with sterile saline) by rolling over conjunctiva. When only one eye is infected, sampling both can help distinguish indigenous microflora from true pathogens. For corneal scrapings, scrape ulcers and lesions with sterile spatula and inoculate scraping directly onto media. Prepare smears by rubbing material onto 1-2 cm area of slide. For vitreous fluid, prepare eye for needle aspiration of fluid and transfer fluid to sterile tube.	
			Methodology: Culture, Identification	
			Clinical Info: Conjunctivitis is usually caused by bacteria or viruses associated with upper respiratory tract infections. Organisms comprising skin and mucous membrane flora (eg, coagulase negative staphylococci, diphtheroids, viridans group streptococci) are generally considered non-pathogenic when recovered from the conjunctival mucosa, but pathogenic if recovered from the surface or interior of the eye (especially in patients who have had cataract or LASIK surgery). Corneal infections (eg, keratitis) are usually associated with ocular trauma, complications of cataract surgery, or improper care/use of contact lens. Endophthalmitis, diagnosed by aspiration of vitreous or aqueous fluid or biopsy, may result from exogenous introduction of pathogens into the eye during trauma or post-surgery, as well as endogenous spread from the bloodstream. Anaerobic cultures require a separate order.	
			Days Performed: Sunday-Saturday	
			Reported: 7 Days	
			<b>CPT:</b> 87070x1 <b>Price:</b> \$46.00	
Eye Culture and Stain	EYECSM	90203	Specimen Requirement: Unspecified scrapings in a sterile container; Ambient. Place scrapings directly on culture media plates. Media is available through the microbiology laboratory for direct inoculation, particularily for corneal scrapings.  Unspecified body fluid in a sterile container; Ambient.  Unspecified drainage in a sterile container; Ambient.	10/1/2014
			Special Info: Media and incubation conditions are employed for the recovery of aerobic bacteria. For conjunctival specimens, sample each eye with separate swabs (premoistened with sterile saline) by rolling over conjunctiva. When only one eye is infected, sampling both can help distinguish indigenous microflora from true pathogens. For corneal scrapings, scrape ulcers and lesions with sterile spatula and inoculate scraping directly onto media. Prepare smears by rubbing material onto 1-2 cm area of slide. For vitreous fluid, prepare eye for needle aspiration of fluid and transfer fluid to sterile tube.	
			Methodology: Culture, Identification, Gram Stain	
			Clinical Info: Conjunctivitis is usually caused by bacteria or viruses associated with upper respiratory tract infections. Organisms comprising skin and mucous membrane flora (eg, coagulase negative staphylococci, diphtheroids, viridans group streptococci) are generally considered non-pathogenic when recovered from the conjunctival mucosa, but pathogenic if recovered from the surface or interior of the eye (especially in patients who have had cataract or LASIK surgery). Corneal infections (eg, keratitis) are usually associated with ocular trauma, complications of cataract surgery, or improper care/use of contact lens. Endophthalmitis, diagnosed by aspiration of vitreous or aqueous fluid or biopsy, may result from exogenous introduction of pathogens into the eye during trauma or post-surgery, as well as endogenous spread from the bloodstream. Anaerobic cultures require a separate order.	
			Days Performed: Sunday-Saturday  Reported: 7 Days	
			<b>CPT:</b> 87205x1, 87070x1	

 $9500 \; \text{Euclid Avenue} \; \mid \; \text{Cleveland, Ohio 44195} \; \mid \; 216.444.5755 \; \mid \; 800.628.6816 \; \mid \; \text{clevelandcliniclabs.com}$ 

11

**Price:** \$69.00

Test Name	Order Code	Billing Code	Test Information	Effective Date
Fibrosprect II	FS2	90206	Specimen Requirement: 2.0 mL serum - SST (GOLD - 1.0 mL minimum) or 2.0 mL serum - red top tube (1.0 mL minimum); Refrigerated  Methodology: Nephelometry (NEPH) , Enzyme-Linked Immunosorbent Assay (ELISA)  Days Performed: Monday-Friday  Reported: 4-7 Days  CPT: 83520x2, 83883x1  Price: \$288.00	10/23/2014
FISH for Angiosarcoma MYC Amplification	МҮСАМР	90214	Specimen Requirement: 6 Slides, unstained; Ambient. Cut six 4 um thin sections from formalin-fixed, paraffin-embedded tissue ONLY, and apply to silanized or positively charged slides. Allow to air dry. The first section and the last section are to be processed for H&E Stains  Alternate - 1 block, formalin-fixed paraffin. Formalin-fixed, paraffin-embedded tissue ONLY. The tissue blocks may be handled routinely; no special storage or handling requirements are required.  Special Info: Proper selection of tissue for analysis is the responsibility of the pathologist.  If there is not enough or no tumor present on the H&E stained slide, a new specimen block or slide is required.  Methodology: Fluorescent In-Situ Hybridization (FISH)  Days Performed: 3 days per week  CPT: 88368x1  Price: \$918.00	9/15/2014
Histoplasma Antigen by EIA, Body Fluid	HISTBF	90324	Specimen Requirement: 2.0 mL Cerebrospinal fluid (CSF) in a sterile container (0.8 mL minimum); Refrigerated.  2.0 mL Bronchoalveolar lavage (BAL) sterile container (0.5 mL minimum); Refrigerated.  2.0 mL Body fluid in a sterile container (0.5 mL minimum); Refrigerated.  2.0 mL Plasma EDTA (lavender - 1.2 mL minimum) or sodium citrate (light blue - 1.2 mL minimum); Refrigerated.  Special Info: Sodium hydroxide is an interferring substance.  Methodology: Enzyme Immunoassay (EIA)  Clinical Info: The MVista® histoplasma quantitative antigen test aids the diagnosis of histoplasmosis. Monitoring the histoplasmosis helps determine when treatment can be stopped and to diagnose relapse  Days Performed: Monday-Friday  Reported: 3-5 Days  CPT: 87385x1  Price: \$165.00	12/4/2014
Histoplasma Antigen by EIA, Serum	HISTOS	90323	Specimen Requirement: 2.0 mL Serum - no additive SST (Gold - 1.0 mL minimum); Refrigerated.  Methodology: Enzyme Immunoassay (EIA)  Days Performed: Sunday-Saturday  Reported: 2-3 Days  CPT: 87385x1  Price: \$100.00	12/4/2014

Test Name	Order Code	Billing Code	Test Information	Effective Date
HIV-1 RNA, Qual TMA	HIVTMA	90207	Specimen Requirement: 1.6 mL Plasma - EDTA (Lavender - 0.6 mL minimum); Frozen. Alternate - 1.6 mL Plasma - EDTA PPT (white); Frozen. 1.6 mL Plasma ACD A (Yellow); Frozen. 1.6 mL Plasma - sodium citrate (Lt. Blue); Frozen.	10/16/2014
			<b>Special Info:</b> Separate plasma from the cells by centrifugation within 24 hours after collection. Transfer the plasma or serum to a plastic screw-cap vial.	
			Clinical Info: The APTIMA® HIV-1 RNA, Qualitative assay may be used: 1. As an aid in the diagnosis of acute and primary HIV-1 infection. 2. To confirm HIV-1 infection in persons who repeatedly test positive for HIV-1 infection. 3. To resolve indeterminate or inconclusive HIV-1 Western blot results.	
			Days Performed: Monday, Wednesday, Friday	
			Reported: 3-7 Days	
			<b>CPT:</b> 87535x1	
			<b>Price:</b> \$290.00	
HIV-2 Antibody Confirmation, Serum	HIV2CN	90312	<b>Specimen Requirement:</b> 0.5 mL Serum - no additive SST (Gold - 0.2 mL minimum); Frozen.	11/20/2014
			Methodology: Line Immunoassay (INNO-LIA)	
			Clinical Info: Confirmation of the presence of HIV-2 antibodies in patients with repeatedly reactive combined HIV-1 and HIV-2 antibody or HIV-2 antibody-only screening test results diagnosis of HIV-2 infection	
			Days Performed: Monday	
			Reported: 7-12 Days	
			<b>CPT:</b> 86689x1	
			<b>Price:</b> \$57.80	
MRSA/Staph Aureus Culture Screen	SANSAL	90201	Specimen Requirement: Place swab(s) in a sterile container; Ambient. Specify site. Swabs must be placed in either Amies or Stuart's bacterial transport medium.  Methodology: Culture	10/1/2014
			Days Performed: Sunday-Saturday	
			Reported: 7 Days	
			<b>CPT:</b> 87081x1	
			<b>Price:</b> \$35.00	
OVA1	OVA1	90148	<b>Specimen Requirement:</b> 2.2 mL Serum (1.1 mL minimum); Refrigerated. <b>Methodology:</b> Electrochemiluminescence (ECLIA), Fixed Rate Time Nephelometry	10/2/2014
			Days Performed: Monday-Saturday	
			Reported: 2 Days	
			<b>CPT:</b> 84999x1	
			<b>Price:</b> \$650.00	
Reducing Substances, Urine	URED	90303	<b>Specimen Requirement:</b> 10.0 mL Random urine in a clean container (5.0 mL minimum); Refrigerated.	10/16/2014
			Methodology: Chemical	
			Days Performed: Sunday-Saturday	
			Reported: 8 Hours	
			CPT: 81005x1	
Sinus Culture and Stain	SINUSC	90202	Price: \$30.00  Specimen Requirement: 1.0 mL Aspirate(s) in a sterile container - Sinus	10/1/2014
			aspirate; Ambient.	
			Methodology: Culture, Identification, Gram Stain  Days Performed: Sunday-Saturday	
			Reported: 7 Days	
			<b>CPT:</b> 87205x1, 87070x1	
			Price: \$69.00	

Test Name	Order Code	Billing Code	Test Information	Effective Date
Tramadol and Metabolite, Quant	TRAQNT	90289	Specimen Requirement: 10.0 mL Random urine in a clean container - no preservatives (2.5 mL minimum); Refrigerated.  Methodology: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)  Days Performed: 4 days a week  Reported: 2-5 Days  CPT: 82542x1  Price: \$77.00	10/27/2014
VMA, Urine 24 Hr	UVMA24	90307	Specimen Requirement: 1.0 mL Urine, 24- hour (well-mixed) in a clean, leak proof, container (no preservatives - 0.3 mL minimum); Refrigerated.  Methodology: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)  Reference Range: 15-99 years: 0.0-8.0 mg/d  Days Performed: 2 days per week  Reported: 1-9 Days	10/6/2014
VMA, Urine Random	UVMAR	90305	Specimen Requirement: 1.0 mL Urine, random in a clean, leak proof, container (no preservatives - 0.3 mL minimum); Refrigerated.  Methodology: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)  Reference Range: 0-11 months: 0.0-27.0 mg/g CRT 12-23 months: 0.0-18.0 mg/g CRT 2-4 years: 0.0-13.0 mg/g CRT 5-9 years: 0.0-8.5 mg/g CRT 10-14 years: 0.0-7.0 mg/g CRT 15-99 years: 0.0-6.0 mg/g CRT Days Performed: 2 days per week Reported: 1-9 Days	10/6/2014
Voltage Gated Potessium Channel Ab	VGKCAB	90284	Specimen Requirement: 4.0 mL Serum - no additive SST (Gold - 0.5 mL minimum); Refrigerated. Separate serum from cells within 1 hour.  Alternate - 4.0 mL Serum - no additive (Red - 0.5 mL minimum); Refrigerated. Separate serum from cells within 1 hour.  Special Info: Screening test for voltage-gated potassium channel (VGKC) antibody receptor complex-associated autoantibodies. Assay does not identify Contactin Associated Protein 2 (CASPR2) Antibody or Leucine-rich Glioma Inactivated 1 Protein (LGI1) antibodies individually.  Methodology: Quantitative Radioimmunoassay  Clinical Info: Voltage-Gated Potassium Channel (VGKC) antibodies are associated with neuromuscular weakness as found in neuromyotonia (also known as Issacs' syndrome) and Morvan syndrome. VGKC antibodies are also associated with paraneoplastic neurological syndromes and limbic encephalitis; however, VGKC antibody-associated limbic encephalitis may be associated with antibodies to leucine-rich, glioma-inactivated 1 protein (Lgi1) or contactin-associated protein-2 (Caspr-2) instead of potassium channel antigens. The clinical significance of this test can only be determined in conjunction with the patient's clinical history and related laboratory testing.  Days Performed: Tuesday  Reported: 2-10 Days  CPT: 83519x1  Price: \$230.00	10/23/2014

Test Name	Order Code	Billing Code	Test Information	Effective Date
Wound Culture and Stain	WCUL	90176	Specimen Requirement: Place in a sterile container; Ambient. Purulent material should be transferred to a sterile container or anaerobe trasnport vial if an anaerobe culture is required.  Swab(s) in Amies media; Ambient. Routine culture swabs should be submitted in a transport system with Stuart's or Amies medium.  Aspirate(s) in a sterile container; Ambient.	10/1/2014
			Special Info: Media and incubation conditions are employed for the recovery of aerobic bacteria from an abscess, lesion or wound. Aspirates of purulent material are superior to swab specimens. Prior to specimen collection, remove surface exudate by cleansing with sterile saline or 70% alcohol and then aspirate with needle and syringe. Transfer aspirate fluid to a sterile container (or Port-A-Cul <sup>TM</sup> vial if anaerobic culture is also ordered). If a swab specimen must be used, a flocked swab (e.g., Eswab <sup>TM</sup> ) is preferred because it collects more material than standard swabs.	
			Methodology: Culture, Identification, Stain	
			Clinical Info: Provision of specific information regarding the specimen site is essential for culture interpretation. Submission of superficial wound specimens is not valuable because the culture usually yields commensal flora which is difficult to distinguish from underlying bacteria responsible for the infection. Traumatic, post-surgical, and diabetic foot infections are often polymicrobial requiring an additional anaerobic culture order to recover all bacterial pathogens. The optimal specimen to diagnose skin and soft tissue infections is a biopsy sample (see tissue culture).	
			Days Performed: Sunday-Saturday	
			Reported: 7 Days	
			<b>CPT:</b> 87205x1, 87070x1	
			<b>Price:</b> \$69.00	

#### Fee Increases

Test Name	Order Code	Billing Code	List Fee	CPT Codes	Effective Date
Cryptococcus Ag Detection	CAD	75306	\$48.00	86403x1	1/2/2015
T Cell V-Beta Flow Cytometry	TVBETA	82594	\$747.00	88184x1 88189x26 88185x1	10/1/2014

#### Fee Reductions

Test Name	Order Code	Billing Code	List Fee	CPT Codes	Effective Date
Cyto P450 2C19 Genotype	2C19PL	88307	\$325.00	81225x1	10/30/2014
Routine Body Fluid Analysis	ROUBFL	31	\$74.00	89051x1 84157x1	10/2/2014

#### **Discontinued Tests**

Test Name	Order Code	Billing Code	Test Information	Effective Date
5-Hydroxyindoleacetic Acid, Urine	U5HIAA	89593	Test discontinued. Replaced by UHIAAD or UHIAR2.	10/6/2014
Diagnostics CFTR Intron 8	CFTR	80937	Test discontinued. Lab use only.	11/11/2014
Histoplasma Capsulatum Antigen	SHISTO	83008	Test discontinued. Replaced by HISTOS and HISTBF.	12/4/2014
HIV-2 IgG Abs, Confirmation	HIV2WB	78717	Test discontinued.	9/18/2014
Immunoglobins, Fluid	FIG	78204	Test discontinued.	9/30/2014
Immunoglobins, Urine	UIG	79142	Test discontinued.	9/30/2014
Legionella Antibodies	LEGAB	75514	Test discontinued.	9/30/2014
Monoclonal Protein, Fluid	FMPA	77079	Test discontinued.	9/30/2014
Protein Electrophoresis, Fluid	FPE	78209	Test discontinued.	9/30/2014
Respiratory Synctial Virus Abs IgG and IgM	RSVGM	79802	Test discontinued.	8/4/2014
Tramadol and Metabolite, Quant	TRACON	82606	Test discontinued. Replaced by TRAQNT.	10/27/2014
Tramadol Screen	TRAMSC	82605	Test discontinued. Replaced by TRAQNT.	10/27/2014
VMA, Urine	UVMA3	80050	Test discontinued. Replaced by UVMA24 or UVMAR.	10/6/2014